Table 2.

CAR-T cell therapy and ASCT.

Similarities	Differences
A similar work-up of blood counts and viral serology tests are required	ASCT is approved in frontline, while CAR-T is currently only approved in patients previously exposed to a PI, IMiD and anti-CD38 mAb
The same leukapheresis machine can be used	Baseline neurological evaluation is required for CAR-T but not ASCT
The same cardiological and respiratory work up can be performed with echocardiogram +/- respiratory test if the patient has respiratory problems	There are clear guidelines for contraindications of ASCT, but these are not currently as well defined for CAR-T
Experience from the multidisciplinary team for transplantation can be leveraged for CAR-T cell therapy and the care of patients with MM	Patients undergo ASCT with low burden of disease after induction therapy. Burden of disease may be higher before CAR-T, but this has been associated with worse adverse events
	In contrast to cells for ASCT, CAR-T cells are considered a drug, which requires involvement from pharmacists
	Adverse event profiles
	The patient journey, including time spent as an inpatient